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White matter abnormalities in drug-naı̈ve
patients with obsessive–compulsive disorder:
a Diffusion Tensor Study before and after
citalopram treatment
Introduction
Neuroanatomical studies of obsessive–compulsive
disorder (OCD) have reported various regional
abnormalities in the gray matter, including the
orbitofrontal cortex, basal ganglia, thalamus, and,
sometimes, the parietal cortex (1–4). In addition,
functional neuroimaging studies have shown
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Objective: The aim was to investigate the white matter abnormalities
of drug-naı̈ve patients with obsessive–compulsive disorder (OCD)
using diffusion tensor-imaging and the white matter changes in the
patients after pharmacotherapy.
Method: Thirteen drug-naı̈ve OCD patients and 13 age- and sex-
matched healthy comparison subjects were examined using diffusion
tensor-imaging and structural magnetic resonance imaging.
Measurements were made in OCD patients before and after 12 weeks
of citalopram treatment.
Results: Compared with controls, the drug-naı̈ve OCD patients
showed significant increases in fractional anisotropy (FA) in the corpus
callosum, the internal capsule and white matter in the area
superolateral to the right caudate. The increases in FA were mostly no
longer observed in patients after 12 weeks of treatment compared with
controls.
Conclusion: Our findings suggest that white matter alterations are
associated with the pathophysiology of OCD, and the abnormalities
may be partly reversible with pharmacotherapy.
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Significant outcomes
• Results suggest that white matter alterations are associated with the pathophysiology of obsessive–
compulsive disorder.
• White matter alterations in obsessive–compulsive disorder may be partly reversible with pharmac-
otherapy.
Limitations
• The small sample size in each group may be related to type II errors potentially causing false negative
results such as lack of difference in the white matter integrity in other regions and the absence of
significant correlations between OC symptoms and FA values.
• The treatment period was relatively short.
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abnormal hyperactivation in the prefrontal cortex,
cingulate cortex, basal ganglia, and thalamus in
most neutral-state (5–7) and symptom-provocation
tasks (8–10). These findings have implicated a
dysfunctional cortico-striato-thalamo-cortical cir-
cuit in the pathophysiology of OCD, rather than a
deficit in distinct regions. The cortical and sub-
cortical regions in this circuit are physically and
functionally connected through the white matter.
Therefore, the white matter in patients with OCD
might show some alterations associated with the
dysfunction of the cortico-striato-thalamo-cortical
circuit at the microstructural level.
Some neuroimaging studies have examined the
white matter in OCD, using morphometric meas-
urements and reported inconsistent findings, such
as no significant difference in the frontal and
anterior cingulate white matter regions (11, 12) and
reduced white matter volume in the sub-cortical
occipito-temporal region of the right hemisphere
(13) or in the posteroinferior pericallosal, retrocal-
losal, and cerebellar regions in OCD patients
compared with healthy controls (14). In addition
to volume studies, a larger corpus callosum (15)
and greater white matter concentration in the
anterior genu of the corpus callosum (16) were
observed in drug-naı̈ve pediatric patients with
OCD and higher concentration of parietal Cho/
Cr was reported in parietal white matter of OCD
patients (17).
Diffusion tensor-imaging (DTI) is a non-inva-
sive technique allowing the in vivo examination of
the white matter fiber tract integrity through
fractional anisotropy (FA). Compared with volu-
metric measurements, this method is potentially
more sensitive to detecting subtle and early
changes in the microstructure and organization
of white matter fiber tracts. Recently, one study
showed that the FA was lower bilaterally in the
anterior cingulate gyrus white matter and the
parietal region, right posterior cingulate gyrus,
and left occipital lobe in medicated patients with
OCD, compared with healthy volunteers, whereas
no areas with a significantly higher FA were
observed (18).
To the best of our knowledge, however, the
white matter integrity in drug-naı̈ve OCD patients
has not yet been investigated. Because many
studies have reported that pharmacological treat-
ment affects the regional volumes (19), glucose
metabolism (6, 20–25), and chemical metabolism
(26) in the brain of OCD patients, it may be
meaningful to investigate the white matter connec-
tivity in drug-naı̈ve OCD patients and the effect of
pharmacotherapy to understand the pathophysiol-
ogy of OCD.
Aims of the study
The aims of this study were to investigate white
matter abnormalities in drug-naı̈ve OCD patients
compared with healthy controls using DTI and to
reveal whether the abnormal structural integrity
would change on treatment with citalopram.
Instead of a region-of-interest approach, we used
a voxel-based analysis to detect changes in the
white matter throughout the brain. We hypothes-
ized that white matter integrity in OCD would
increase in some regions of cortico-striato-thalamic
circuits. We also predicted that sufficient treatment




The subjects had participated in our previous
proton magnetic resonance spectroscopic imaging
(1H-MRSI) study (26). Detailed subjects and
pharmacotherapy protocol have been described in
that report. Briefly, 13 patients (eight men, five
women) who fulfilled the DSM-IV criteria for
OCD, as diagnosed with the Structured Clinical
Interview for DSM-IV Axis I disorders (SCID-I)
(27) and 13 sex- and age-matched normal controls
were recruited. There were no significant differ-
ences with regard to age (mean ± SD age,
27.8 ± 7.3 for OCD patients; 26.9 ± 7.0 for
controls; t24 ¼ )0.33; P ¼ 0.75), or mean IQ
(109.8 ± 13.4 for OCD patients; 117.4 ± 15.9
for controls; t24 ¼ 1.32; P ¼ 0.20), as estimated
by the Korean version of Wechsler Adult Intelli-
gence Scale (K-WAIS) (28). All subjects were right-
handed Koreans. The clinical characteristics of the
patients sample are presented in Table 1. Two of
the OCD patients had major depressive disorders
and one patient had dysthymic disorder as comor-
bidity. Patients were drug-naı̈ve except one who
had taken medication for a few days, several years
prior to the study. The present study was approved
by the local institutional review board, and written
informed consent was obtained from all the sub-
jects after the procedures were fully explained.
For the 12-week pharmacotherapy, citalopram
treatment was started at 10 mg/day, and titrated
up to 60 mg/day by the sixth week, increasing by
10 mg every week. It was then maintained at
60 mg/day until the end of the 12-week pharmac-
otherapy regimen.
The OCD symptom severity was measured using
the Yale-Brown Obsessive Compulsive Scale (Y-
BOCS) (29). The Hamilton Depression Rating
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Scale (HDRS) (30), the Beck Depression Inventory
(BDI) (31), and the Beck Anxiety Inventory (BAI)
(32) were also administered both before and after
pharmacotherapy.
Diffusion tensor-imaging scans were performed
on patients before and after pharmacotherapy and
healthy controls, also, all patients completed the
procedures and evaluation without dropouts.
Image-acquisition
Three-dimensional T1-weighted magnetic reson-
ance imaging (MRI) and DTI studies were per-
formed, using a 1.5-T MR scanner (Philips Medical
Systems, Best, the Netherlands). Firstly, we
acquired a high-resolution 3D T1-weighted MRI
volume data set with the following parameters:
repetition time (TR) 25 ms, echo time (TE) 6.9 ms,
flip angle 40, 256 · 256 acquisition matrix, and
240-mm field of view, contiguous 150 axial slices.
In the whole-brain DT-MRI examination, sets of
axial diffusion-weighted single-shot echo-planar
images were collected with the following parame-
ters: 128 · 128 acquisition matrix, 1.71 · 1.71 ·
4 mm3 voxels; reconstructed to 0.86 · 0.86 ·
4 mm3; 40 axial slices; 220-mm field of view; TE
62 ms,TR7390 ms;Flip angle 90; slice gap 0 mm; 3
averaging per slice; b-factor of 600 smm)2. With the
baseline image without weighting [0, 0, 0], diffusion-
weighted images were acquired from six different
directions.
All axial sections were acquired parallel to the
anterior commissure-posterior commissure line.
Data-processing
Magnitude Fourier-transformed images were
transferred in DICOM format, then converted
into ANAYZE 6.0 (Mayo foundation, Rochester,
MN, USA) readable form, using in-house written
Matlab (MathWorks Inc., Natick, MA, USA)
routines. The diffusion-weighted images were cor-
rected for spatial distortions induced by eddy
currents using the modified SPM99 (Wellcome
Department of Cognitive Neurology, Institute of
Neurology, University College London, UK) algo-
rithm to minimize mutual information between the
diffusion-unweighted and -weighted images. Diffu-
sion tensor matrices from sets of seven diffusion-
weighted images were generated and then, the three
eigenvalues (ki ¼ 1, 2, 3) and eigenvectors (ei ¼ 1,
2, 3) were calculated via matrix diagonalization.
FA maps were generated according to the conven-
tional method (33).
Image-processing methods were based on a
voxel-based morphometry technique (34) and
implemented in SPM2 (http://www.fil.ion.ucl.a-
c.uk/spm/). A standard template was created
specifically for the study in order to match more
closely the population under investigation and the
image-acquisition protocols used by Good et al.
(34) For the customized template creation, the B0
DTI volumes from the OCD patients and the
control subjects were spatially normalized to the
standard T2-MRI template, based on 152 healthy
subjects from the Montreal Neurological Institute.
The spatially normalized B0 images were averaged
to provide the template in stereotactic space.
Subsequently, the B0 images from all OCD patients
and control subjects were spatially normalized to
the customized template. The parameters resulting
form this spatial normalization step were then
applied to the FA map of each subjects. Thus, we
obtained 26 FA maps of matrix size and voxel size
2 · 2 · 2 mm3 in common Talairach space. Both
the registered FA images were smoothed with an
isotropic Gaussian kernel (10-mm full width at half
maximum).
Table 1. Demographic and clinical characteristics of
patients with OCD and controls






Sex (M/F) 8/5 8/5
Age (years), mean (SD) 27.8 (7.3) 26.9 (7.0) )0.33 0.75
Education (years), mean (SD) 15.3 (1.8) 15.1 (2.9) )0.24 0.81
Estimated IQ 109.8 (13.4) 117.4 (15.9) 1.32 0.20
Clinical characteristics
Illness duration (years), mean (SD) 7.2 (9.0)
Pretreatment Post-treatment
YBOCS score, mean (SD) 30.2 (4.6) 16.6 (6.4) ) 8.76 <0.001
HDRS score, mean (SD) 12.5 (7.6) 6.2 (4.6) ) 3.14 0.009
BAI score, mean (SD) 22.2 (12.2) 11.5 (7.9) ) 3.80 0.003
BDI score, mean (SD) 17.9 (9.8) 9.2 (7.1) ) 3.68 0.003
SD, standard deviation; Y-BOCS, Yale-Brown Obsessive Compulsive Scale; BAI, Beck Anxiety Inventory; BDI, Beck
Depression Inventory; HDRS, Hamilton Depression Rating Scale; OCD, obsessive–compulsive disorder.
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Statistical analyses
Between-group statistical comparisons of demogra-
phic variables were performed with independent
t-tests. Paired t-tests were employed to compare pre-
to post-treatment Y-BOCS scores, BAI scores,
HDRS scores and BDI scores in OCD patients.
A level ofP < 0.05was considered to be significant.
These smoothed images for patients with OCD
and controls were compared using voxel-wise t-test
statistics. The t-test and paired t-test were done to
be compared with FA images between drug-naı̈ve
patients with OCD and controls and between
before and after 12-week treatment within the
patient group. The SPM (t) maps were then
transformed to the unit normal distribution and
thresholded at P < 0.001 (uncorrected) and only
the clusters of more than 20 contiguous voxels were
considered in the analysis. This combination of a
level and cluster size was chosen to provide
protection against type I error.
To investigate the correlation between the FA
values and clinical characteristics, we examined the
correlates using Spearman’s rank correlation coef-
ficient (rs). The FA values were computed in the
regions showing higher or lower FA within the
patient group compared with controls using a
volume of interest (VOI) module of SPM2. Fur-
thermore, the correlations between the changes of
FA values from baseline to follow-up and the
changes of the clinical measures were investigated.
Results
All clinical measures in the OCD patients
improved significantly after 12 weeks of citalopram
treatment (Table 1). On comparing drug-naı̈ve
OCD patients and controls, significantly higher
FA in the OCD patients was observed in the
corpus callosum extending to the temporal lobe
(tapetum), the white matter around the lentiform
nucleus, including the posterior limb and retrolen-
ticular part of the internal capsule bilaterally, and
the lateral aspect of the right caudate nucleus
(Table 2, Fig. 1). Significantly lower FA was not
observed in any part of the brain white matter in
drug-naı̈ve OCD patients compared with control
subjects. We also compared the FA maps between
only 10 OCD patients without comorbid mood
disorder and 13 healthy controls to determine
whether the comorbid mood disorder impacts the
FA differences. We did not find significant differ-
ence between the result of all patients and the result
of patients with OCD alone.
Examination of the change in FA in the OCD
patients with pharmacotherapy revealed a signifi-
cant pre- to post-treatment decrease in FA in the
posterior thalamic radiation on the right parietal
lobe (Fig. 2). The Talairach co-ordinates repre-
senting the centroid (x ¼ right, y ¼ anterior, and
z ¼ superior) were x ¼ 34, y ¼ )41, and z ¼ 30,
and the cluster size was 34 voxels. However,
pharmacotherapy did not lead to an increase in
FA in any brain region in the patients. In addition,
no increases in FA in drug-naı̈ve OCD patients,
compared with healthy controls, were observed
after 12 weeks of treatment, except for the body of
the left corpus callosum (44 voxels, maximal Z-
score ¼ 3.56, co-ordinatesx,y,z ¼ )30, )38, 24) and
the right superior temporal region (53 voxels,
maximal Z-score ¼ 3.94, co-ordinatesx,y,z: 42,
)24, 12) (Fig. 3).
We also examined the clinical correlates of FA
within the drug-naı̈ve OCD patient group. We
computed the average FA values for each of the six
regions in which the FA differed significantly
between the two groups. These investigations
showed that none of the clinical measures, such
as the Y-BOCS, HDRS, BDI, and BAI, was
significantly correlated to FA. Furthermore, the
change in FA in the regions showing FA differ-
ences from the baseline to the follow-up was not
correlated to the changes in the scores of the
clinical measures and not with clinical character-
Table 2. Regions showing significant increases of
FA value in patients with obsessive–compulsive





Left corpus callosum extending into temporal lobe )18 )38 30 979 4.64
Left retrolenticular part of internal capsule )40 )28 10 4.44
Right corpus callosum 22 )32 27 314 4.43
Right retrolenticular part of internal capsule 42 )21 10 126 4.04
Left posterior limb of internal capsule )22 )2 )7 190 3.97
Right posterior limb of internal capsule 22 0 )7 200 3.93
Supero-lateral area of the right caudate nucleus 24 )4 17 117 3.58
FA, fractional anisotropy.
*Foci for significant differences are listed (P < 0.001, uncorrected). Co-ordinates represent the location of the
maximum pixel values in Talairach space.
The voxels of the region were included in the same cluster of left corpus callosum extending into temporal lobe.
Voxel number of 979 represented number of voxels in these two regions.
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istics such as age, duration of illness and the age of
the onset.
Discussions
We found abnormalities in the white matter
integrity in drug-naı̈ve OCD patients compared
to healthy control subjects that were reversible on
treatment. Increases in the FA in drug-naı̈ve OCD
patients were observed in the white matter in the
corpus callosum extending into the temporal lobe
(tapetum) and in the white matter around the
thalamus and corpus striatum. These structures are
key regions in the pathophysiology of OCD,
and these changes indicate dysfunction of the
cortico-striato-thalamo-cortical circuit. Moreover,
Fig. 1. Voxels showing increases of
fractional anisotropy in drug-naı̈ve
patients with obsessive–compulsive
disorder compared to controls (thresh-
old P < 0.001, uncorrected), mapped
onto an average T1-weighted image of
control and obsessive–compulsive dis-
order brains. The colour scale indicates
the magnitude of Z-values.
Fig. 2. Voxels showing pretreatment to
post-treatment fractional anisotropy
decrease within patients with obsessive–
compulsive disorder in the right pos-
terior thalamic radiation mapped onto
an average T1-weighted image (thresh-
old P < 0.001, uncorrected).
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the findings were interesting because increases in
glucose metabolism or cerebral blood flow have
been consistently observed in these regions, inclu-
ding the prefrontal area, anterior and posterior
cingulate cortex, and thalamus (6–8, 35–38). Neu-
rodevelopmentally, increases in FA due to axonal
growth or myelination are observed in the normal
brain until young adulthood (8–12 years), whereas
there is very little change in young adults (21–
27 years) (39). However, the physiological basis of
the pathologic alterations in the FA remains
unclear. Rosas et al. (40) suggested that the
increase in FA could be a pathological process
that modifies tissue-integrity, such as neuronal
remodeling or loss. From this perspective, an
increase in FA might be a pathologic process
caused by this neuronal change in OCD because a
higher rate of the co-occurrence of OC symptoms
is observed in epilepsy (41) and brain injury (42)
leading to remodeling of neurons.
The increase in FA is generally proposed to be
related to a higher density, more directional
coherence, and greater degree of myelination of
fibers; these factors could contribute to more rapid
or greater information transmission functionally
(43). Perhaps the higher FA in OCD patients
represents a rapid or increased information trans-
mission caused by filtering failures at the level of
the thalamus. A deficiency in modulation via the
cortico-striato-thalamic pathways is one of the
models that explain the intrusive events, i.e. it is
the hallmark of OCD. According to this scheme,
excitation or disinhibition at the thalamus results
from overdriving the cortico-thalamic branch, and
the positive feedback loops between the cortex and
thalamus might mediate circular and repetitive
thoughts (10, 44). Therefore, it is interesting to
note that the increases in FA in drug-naı̈ve OCD
patients were observed mostly in the regions that
contain thalamic radiations, such as the posterior
limb and the retrolenticular part of the internal
capsule and the superolateral area of the caudate,
which are penetrated by posterior, superior, and
anterior thalamic radiations respectively (45).
The other regions showing increased FA were
the corpus callosum extending into the temporal
lobe, especially the superior temporal region in
both hemispheres. The corpus callosum is an
important white matter structure that plays a
critical role in inter-hemispheric communication
(46, 47), and the superior temporal region also has
rich reciprocal interconnections with other cortical
and sub-cortical areas, such as the orbitomedial
frontal areas (48), putamen, and caudate nucleus
(49), where we also found increased FA. Cottraux
et al. (37) reported that OCD patients who have
checking rituals have greater regional cerebral
blood flow (rCBF) in the superior temporal regions
in the resting state, and that the processing of both
obsessive and neutral stimulation increases the
rCBF, based on the findings of a study using
functional MRI. Choi et al. (50) also reported
significant volume reductions in the superior
temporal gyrus in OCD patients.
We also found that the increased FA was
normalized after 12 weeks of citalopram treatment
in most of the regions showing higher FA in drug-
naı̈ve OCD patients compared with healthy con-
trols. This finding concurs with the results of
previous pre- and post-treatment neuroimaging
studies in which the hyperactivity in the frontal-
sub-cortical circuits in untreated OCD patients was
normalized in response to treatment (24, 51, 52).
White matter FA changes have been reported in
both the normal aging process and in disease
processes with and without treatment (40, 53).
Nobuhara et al. (54) reported white matter FA
changes following electroconvulsive therapy in
patients with depression. The changes of FA with
citalopram treatment could also be resulted from
the improvement of depression, not OCD. To
investigate this possibility, we compared our results
with previous studies. Saxena et al. (51) reported
that subjects with OCD alone showed significant
Fig. 3. Voxels showing significant
increases of fractional anisotropy in
patients with obsessive–compulsive
disorder compared with controls after
12 weeks treatment in the body of left
corpus callosum mapped onto an aver-
age T1-weighted image (threshold
P < 0.001, uncorrected).
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metabolic decreases in the prefrontal cortex, caud-
ate nucleus and thalamus after 8–12 weeks of
treatment with paroxetine hydrochloride. On the
other hand, the major depression disorder (MDD)
and concurrent OCD + MDD groups showed
metabolic decreases only in the prefrontal cortex
and increases in the striatum. We found that
decrease of white matter FA after citalopram
treatment was observed in thalamic radiation
only. This result supports the view that the changes
of white matter FA are more associated with
improvement of OCD rather than depression.
However, further studies with larger subjects are
necessary to determine the effect of MDD.
The OCD group showed a significant pre- to
post-treatment decrease in FA only in the right
posterior thalamic radiation, although most of the
higher FA in drug-naı̈ve patients compared with
healthy controls was no longer seen on the subse-
quent comparison with healthy controls after
pharmacotherapy. Although the 12 weeks of
treatment with citalopram induced a normalization
of FA in drug naive OCD patients compared with
healthy controls, the changes of FA within OCD
patients may be not significant except for one
regions, i.e. the posterior thalamic radiation.
Szeszko et al. (18) reported lower FA in several
regions, including the anterior cingulate gyrus
white matter and posterior cingulate gyrus, and
no increase in FA. These differences in the results
might be an effect of the treatment period or other
subject characteristics such as the younger age,
lower amount of co-morbid illness, and the drug-
naı̈ve state of our subjects, when we consider the
significant decreases in FA after pharmacotherapy.
Moreover, in a previous study using 1H-mag-
netic resonance spectroscopic-imaging (MRSI) of
the same subjects studied here, we found that the
abnormal N-acetylaspartate (NAA) levels in the
prefrontal cortex and frontal white matter of drug-
naı̈ve OCD patients were reversed after 12 weeks
of citalopram treatment (26). Despite the vague
correlations of FA with NAA (55) and the limita-
tion that the regions of interest in the 1H-MRSI
study did not include the thalamus and basal
ganglia, our results may be significant when we
consider that both studies provide evidence of the
reversibility of the neuronal integrity in OCD
patients with pharmacotherapy.
Our study has several limitations. Firstly, the
sample size in each group was small. This may
explain the lack of differences in the white matter
integrity in other regions, including the orbitofron-
tal lobe and striatal regions, and the absence of
significant correlations between OC symptoms and
FA values. Secondly, the treatment period was
relatively short. Because the white matter volume or
integrity changed according to treatment or the
symptomatic state (56–58), the findings after
12 weeks of treatment could change further with
additional treatment. Additional studies should
examine the white matter integrity in OCD patients
for a larger sample size and a longer period of
treatment. Thirdly, the OCD patients were drug-
naı̈ve at baseline and had taken only citalopram.
Therefore, it is difficult to speculate whether our
results would be applicable to patients who are
taking other medications or undergoing cognitive
behavior therapy. Finally, the methodological lim-
itations must be considered. There are some debates
about Voxel-BasedMorphometry methods, such as
the accuracy of normalization and the detection
ability of the precise regions showing differences.
However, we inspected the all images to verify the
normalization.
In conclusion, our findings suggest that white
matter alterations are associated with the patho-
physiology of OCD and the abnormalities may be
partly reversible with pharmacotherapy.
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